Back to results
US 2024/0182567 A1Published application
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
AssigneeNational University of Singapore
InventorsYi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
Claims20
A method of producing an engineered immune cell expressing a chimeric antigen receptor (CAR) targeting CD7, the method comprising:
- (i) introducing into an immune cell:
- (a) a first nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to an endoplasmic reticulum (ER) or Golgi localizing domain, wherein said target-binding molecule is a first antibody that specifically binds to CD7, and
- (b) a second nucleic acid comprises a nucleotide sequence encoding said CAR, wherein said CAR comprises a second antibody that specifically binds to CD7;
- and
- (ii) culturing said immune cell comprising said target-binding molecule linked to said ER or Golgi localizing domain and said CAR, thereby producing said engineered immune cell;
- wherein expression of said target-binding molecule prevents fratricide of said engineered immune cell during step (ii).
3 more elements
Dependencies are inferred from the claim text.